<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533728</url>
  </required_header>
  <id_info>
    <org_study_id>SBG-2-02</org_study_id>
    <nct_id>NCT00533728</nct_id>
  </id_info>
  <brief_title>Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Study to Determine the Safety and Effect of Soluble Beta-Glucan (SBG) in Combination With Rituximab and COP/CHOP in Patients With Non'Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotec Pharmacon ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotec Pharmacon ASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of soluble beta-glucan (SBG) in combination
      with antibody and chemotherapy treatment in patients with non-Hodgkin-s lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soluble beta-glucan (SBG)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CD20 positive B-cell non-Hodgkin's lymphoma

          2. Treatment with rituximab and CHOP or COP

          3. Performance status 0 or 1 according to the WHO scale (Appendix)

          4. Expected lifetime of more than 12 weeks

          5. Age ≥ 18 years

          6. The patient must be able and willing to comply with the study procedures, and signed
             and dated informed consent must be obtained

        Exclusion Criteria:

          1. Women who are pregnant or breast-feeding. For fertile women, a negative pregnancy test
             must be provided during the screening test. Women of childbearing potential must agree
             to use adequate contraception prior to study entry and for the duration of study
             participation

          2. Lymphoma involvement of central nervous system

          3. Reduced bone marrow function defined by leukocyte counts &lt; 3.0 x 109/l, neutrophil
             counts &lt; 1.5 x 109/l, thrombocyte counts &lt; 100 x 109/l or hemoglobin &lt; 10 g/dl

          4. Reduced liver function defined by bilirubin &gt; 1.5 x upper limit of normal (ULN) or
             ASAT/ALAT ≥ 3 x ULN

          5. Reduced renal function defined by serum creatinine ≥ 2 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustav Lehne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet, Kreftklinikken Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>March 2, 2009</last_update_submitted>
  <last_update_submitted_qc>March 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

